Differential hepatoprotective role of the cannabinoid CB
Journal
British journal of pharmacology
ISSN: 1476-5381
Titre abrégé: Br J Pharmacol
Pays: England
ID NLM: 7502536
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
15
04
2019
revised:
19
02
2020
accepted:
02
03
2020
pubmed:
14
3
2020
medline:
22
6
2021
entrez:
14
3
2020
Statut:
ppublish
Résumé
Protective mechanisms of the endogenous cannabinoid system against drug-induced liver injury (DILI) are actively being investigated regarding the differential regulatory role of the cannabinoid CB The 2-arachidonoylglycerol (2-AG)-related signalling receptors and enzymatic machinery, and inflammatory/fibrogenic factors were investigated in the liver of a mouse model of hepatotoxicity induced by acute and repeated overdoses (750 mg·kg Acute paracetamol increased the expression of CB The differential role of CB
Sections du résumé
BACKGROUND AND PURPOSE
Protective mechanisms of the endogenous cannabinoid system against drug-induced liver injury (DILI) are actively being investigated regarding the differential regulatory role of the cannabinoid CB
EXPERIMENTAL APPROACH
The 2-arachidonoylglycerol (2-AG)-related signalling receptors and enzymatic machinery, and inflammatory/fibrogenic factors were investigated in the liver of a mouse model of hepatotoxicity induced by acute and repeated overdoses (750 mg·kg
KEY RESULTS
Acute paracetamol increased the expression of CB
CONCLUSION AND IMPLICATIONS
The differential role of CB
Identifiants
pubmed: 32167157
doi: 10.1111/bph.15051
pmc: PMC7312315
doi:
Substances chimiques
Cannabinoids
0
Receptor, Cannabinoid, CB1
0
Receptor, Cannabinoid, CB2
0
Acetaminophen
362O9ITL9D
ABHD6 protein, human
EC 3.1.1.23
Monoacylglycerol Lipases
EC 3.1.1.23
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3309-3326Subventions
Organisme : Consejería de Salud, Junta de Andalucía
ID : PI-0139-2018
Organisme : Consejería de Salud, Junta de Andalucía
ID : PI-0337-2012
Organisme : Consejería de Salud, Junta de Andalucía
ID : C1-0049-2019
Organisme : Instituto de Salud Carlos III
ID : CP19/00068
Organisme : Instituto de Salud Carlos III
ID : CPII17/00024
Organisme : Instituto de Salud Carlos III
ID : PI16/01374
Organisme : Instituto de Salud Carlos III
ID : PI16/01698
Organisme : Instituto de Salud Carlos III
ID : CP14/00173
Organisme : Instituto de Salud Carlos III
ID : CPII19/00022
Organisme : Instituto de Salud Carlos III
ID : PI17/02026
Organisme : Instituto de Salud Carlos III
ID : PI16/01953
Organisme : Departament d'Innovació, Universitats i Empresa, Generalitat de Catalunya
ID : 2014 SGR 680
Organisme : Agencia de Innovación y Desarrollo de Andalucía
ID : CTS-8221
Informations de copyright
© 2020 The British Pharmacological Society.
Références
J Hepatol. 2013 Oct;59(4):891-6
pubmed: 23567085
J Leukoc Biol. 2015 Jun;97(6):1049-70
pubmed: 25877930
Eur J Pharmacol. 2006 Feb 15;531(1-3):280-1
pubmed: 16438952
Br J Pharmacol. 2019 Dec;176 Suppl 1:S297-S396
pubmed: 31710714
Hepatology. 2014 Jan;59(1):296-306
pubmed: 23813495
Br J Pharmacol. 2007 Dec;152(7):1092-101
pubmed: 17876302
Acta Pol Pharm. 2014 Jan-Feb;71(1):11-23
pubmed: 24779190
Biochem Biophys Res Commun. 2013 Jul 19;437(1):48-54
pubmed: 23806692
Prostaglandins Leukot Essent Fatty Acids. 2002 Feb-Mar;66(2-3):377-91
pubmed: 12052051
J Med Chem. 2017 Feb 9;60(3):1126-1141
pubmed: 28085283
Expert Opin Ther Targets. 2007 Mar;11(3):403-9
pubmed: 17298297
J Lipid Res. 2014 May;55(5):966-77
pubmed: 24610889
Best Pract Res Clin Endocrinol Metab. 2009 Feb;23(1):65-77
pubmed: 19285261
Exp Neurol. 2015 Nov;273:36-44
pubmed: 26244281
Liver Int. 2007 Mar;27(2):215-9
pubmed: 17311616
Int J Obes (Lond). 2007 Apr;31(4):692-9
pubmed: 17224929
Eur J Gastroenterol Hepatol. 2018 Nov;30(11):1283-1290
pubmed: 30169449
Br J Pharmacol. 2012 Apr;165(8):2462-78
pubmed: 21449982
Liver Int. 2018 Aug;38(8):1475-1486
pubmed: 29341392
Front Pharmacol. 2016 Nov 04;7:415
pubmed: 27867358
Prog Neuropsychopharmacol Biol Psychiatry. 2019 Dec 20;95:109677
pubmed: 31228640
Br J Pharmacol. 2020 Jul;177(14):3309-3326
pubmed: 32167157
Br J Pharmacol. 2011 Aug;163(7):1432-40
pubmed: 21457226
J Evid Based Med. 2018 Nov;11(4):272-277
pubmed: 30398032
Gastroenterology. 2010 Dec;139(6):1961-1971.e1
pubmed: 20600015
Hepatology. 2010 Sep;52(3):1046-59
pubmed: 20597071
PLoS One. 2017 Apr 25;12(4):e0176416
pubmed: 28441459
Hepatology. 2007 Jul;46(1):122-9
pubmed: 17526015
Saudi J Gastroenterol. 2013 Jul-Aug;19(4):144-51
pubmed: 23828743
J Immunol. 2015 Oct 1;195(7):3390-401
pubmed: 26320250
Gut. 2019 Mar;68(3):522-532
pubmed: 30301768
Nucleic Acids Res. 2018 Jan 4;46(D1):D1091-D1106
pubmed: 29149325
Pharmacogenomics. 2009 Sep;10(9):1467-87
pubmed: 19761370
Front Pharmacol. 2017 Oct 06;8:705
pubmed: 29056914
Am J Pathol. 2008 Oct;173(4):993-1001
pubmed: 18772330
Drug Metab Dispos. 2011 Sep;39(9):1689-95
pubmed: 21628499
Diabetes. 2006 Nov;55(11):3053-60
pubmed: 17065342
Br J Pharmacol. 2011 Dec;164(7):1899-915
pubmed: 21557739
Br J Pharmacol. 2018 Feb;175(3):407-411
pubmed: 29350411
Nat Med. 2006 Jun;12(6):671-6
pubmed: 16715087
J Pharmacol Pharmacother. 2010 Jul;1(2):94-9
pubmed: 21350617
Br J Pharmacol. 2019 Dec;176 Suppl 1:S21-S141
pubmed: 31710717
Cell Metab. 2008 Mar;7(3):227-35
pubmed: 18316028
J Biol Chem. 2005 Sep 9;280(36):31405-12
pubmed: 15987694
J Pharmacol Exp Ther. 2008 Feb;324(2):475-83
pubmed: 18029545
J Pharmacol Exp Ther. 1973 Oct;187(1):195-202
pubmed: 4746327
Biochim Biophys Acta. 2008 Apr;1781(4):200-12
pubmed: 18316044
Hepatology. 2011 Oct;54(4):1217-26
pubmed: 21735467
Gastroenterology. 2013 Apr;144(4):808-817.e15
pubmed: 23295443
Medicines (Basel). 2018 May 28;5(2):
pubmed: 29843404
Diabetologia. 2010 Dec;53(12):2629-40
pubmed: 20835701
Clin Liver Dis. 2012 May;16(2):231-45
pubmed: 22541696